Krystal Biotech (NASDAQ:KRYS) Issues Earnings Results, Beats Estimates By $0.21 EPS

Key Points

• Krystal Biotech's quarterly earnings report revealed an EPS of $1.29, surpassing expectations by $0.09.
• The company boasts a market capitalization of $4.54 billion with a return on equity of 14.64% and a net margin of 37.17%.
• Wall Street analysts maintain a consensus rating of "Buy" for KRYS, with an average price target of $211.33.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its quarterly earnings data on Monday. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21, Zacks reports. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $2.56 during trading hours on Friday, reaching $138.66. 332,066 shares of the company were exchanged, compared to its average volume of 334,202. The stock's fifty day moving average is $141.71 and its two-hundred day moving average is $155.45. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The company has a market cap of $4.01 billion, a price-to-earnings ratio of 28.18 and a beta of 0.70.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 49,800 shares of company stock valued at $7,487,943 in the last quarter. Corporate insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock valued at $2,870,000 after buying an additional 688 shares during the period. Royal Bank of Canada raised its holdings in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock worth $294,000 after purchasing an additional 964 shares during the period. Empowered Funds LLC acquired a new stake in Krystal Biotech in the first quarter worth $218,000. Finally, AQR Capital Management LLC raised its holdings in Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on KRYS shares. Citigroup reiterated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday. Guggenheim decreased their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America decreased their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Finally, Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $210.22.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).